Study on the glucose-lowering effect and metabolic benefit of SGLT2 inhibitors
Not Applicable
- Conditions
- Diabetes mellitus
- Registration Number
- JPRN-UMIN000052955
- Lead Sponsor
- Department of Internal Medicine, Kurume University School of Medicine
- Brief Summary
The intervention did not induce significant differences in HbA1c between the groups. The dapagliflozin group showed a significant decrease in body fat mass and percentage, along with an increase in skeletal muscle percentage. Among analyzed the 10 urinary biomarkers of diabetic kidney disease, only 3OH propionic acid showed a significant increase in the dapagliflozin-treated group compared to the insulin-treated group, suggesting that dapagliflozin modulates BCAA metabolism primarily in the kidney.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria encompassed pregnant or breastfeeding women, patients with malignant disease, severe infections (including urinary tract infections), severe trauma, or recent surgery.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method